Alamar Biosciences Stock Price, News & Analysis
Company Description
Alamar Biosciences, Inc. develops proteomics technologies for protein detection and analysis. The company’s business centers on its NULISA technology, which stands for NUcleic Acid Linked Immuno-Sandwich Assay, and on a broader Precision Proteomics platform designed to detect and quantify protein biomarkers from small biofluid samples with high sensitivity and specificity.
Alamar sells instruments, consumables, and services based on its proteomic liquid biopsy platform. Its product portfolio includes NULISAseq panels, NULISAqpcr assays, and the ARGO HT fully automated, high-throughput system, which supports a sample-to-answer workflow. The company’s products are used in protein biomarker research, including applications tied to early disease detection and neurodegenerative disease research.
The company operates as a single-segment business focused on developing and commercializing protein-analysis tools. Its revenue model is tied to platform adoption, instrument sales, consumable usage, assay and panel offerings, and related services. Alamar’s customer base includes academic research institutions and biopharmaceutical organizations that use proteomics tools to study disease biology and biomarker signatures.
Alamar Biosciences is incorporated in Delaware and is headquartered in Fremont, California. Its common stock trades on the Nasdaq Stock Market under the symbol ALMR. The company completed its initial public offering in April 2026, after which it adopted amended and restated governing documents as a public company.
Stock Performance
Alamar Biosciences (ALMR) stock last traded at $22.00, down 0.86% from the previous close. At a market capitalization of $1.5B, ALMR is classified as a small-cap stock with approximately 69.3M shares outstanding.
ALMR Rankings
Latest News
Alamar Biosciences has 3 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. Key topics include earnings. View all ALMR news →
SEC Filings
Alamar Biosciences has filed 5 recent SEC filings, including 2 Form SCHEDULE 13D, 1 Form 4, 1 Form 10-Q, 1 Form 8-K. The most recent filing was submitted on May 8, 2026. SEC filings provide transparency into a company's financial condition, material events, and regulatory compliance. View all ALMR SEC filings →
Insider Radar
Insider buying activity at Alamar Biosciences over the past 90 days may reflect management confidence in the company's direction. Institutional investors and analysts often monitor insider purchases as a potential bullish indicator for the stock.
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
ALMR Company Profile & Sector Positioning
Alamar Biosciences (ALMR) operates in the Medical Devices industry within the broader Laboratory Analytical Instruments sector and is listed on the NASDAQ. In monthly performance, the stock ranks #688 among all tracked companies.